 SAN DIEGO, July 6, 2021 PRNewswire -- Heron Therapeutics, Inc. Nasdaq: HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has executed a contract for ZYNRELEF with Apexus, LLC Apexus. Apexus is the designated Prime Vendor for the 340B Drug Pricing Program. 